Skip to main content
Premium Trial:

Request an Annual Quote

Genein, Beckman Coulter, Illumina, Siemens

Premium
Genein of Pusan, South Korea, has received European Patent No. 1791956, “Oligonucleotide for detection of microorganism diagnostic kits and methods for detection of microorganisms using the oligonucleotide.” The patent describes a method of using bacterial-specific, genus-specific, and species-specific oligonucleotides from a variety of specimens or samples for the detection of microorganisms. More specifically, the patent claims bacterial-specific, genus-specific, and species-specific oligonucleotides designed from the target nucleotide sequences of 23S rDNA or ITS gene, PCR kits that use the oligos as a primer, microarrays containing the oligos as probes, and methods for detecting microorganisms by using the oligos. The patent claims the technology can detect the presence of microorganisms such as pathogenic bacteria, bacteria causing food poisoning, and environmental pollutants.
 

 
Beckman Coulter has received US Patent No. 7,229,763, “Assay system using labeled oligonucleotides.” The patent claims an assay method for a target ligand comprising the steps of: a) providing a solid support with a plurality of capture oligonucleotides immobilized on the support; b) adding a plurality of capture ligands  to the support that are then attached to complementary oligonucleotides, where at least a portion of the complementary oligonucleotides have detectable labels directly attached; c) providing conditions suitable for hybridization of the capture oligonucleotides and the complementary oligonucleotides to form double stranded nucleic acid duplexes; d) bringing the target ligand in contact with the solid support under conditions where the target ligand binds to the capture ligand to form a first complex; e) adding a plurality of detector ligands with second detectable labels to the solid support under conditions; f) detecting the first detectable labels; and g) detecting the second detectable labels in the second complex, thereby detecting the target ligand.
 

 
Illumina has received US Patent No. 7,229,769, “Compositions and methods for detecting protease activity.” The patent describes a method of determining the activity of a protease. The method includes the steps of: a) providing a protease substrate including a protein moiety attached to a nucleic acid moiety and a ligand moiety; b) contacting the protease substrate with a protease under conditions where the protease catalyzes cleavage of the protein moiety, thereby producing a proteolytic product where the nucleic acid moiety is separated from at least a portion of the protein moiety and the ligand moiety; c) contacting the proteolytic product with a receptor under conditions where the ligand moiety binds to the receptor to form a complex; d) separating the complex from the nucleic acid moiety, thereby forming a separation product including the nucleic acid moiety; e) contacting the separation product with a probe nucleic acid under conditions where the nucleic acid moiety hybridizes to a complementary sequence of the probe; and f) detecting hybridization of the separation product to the probe, thereby determining activity of the protease.
 

 
Siemens has received US Patent No. 7,227,632, “Assembly for the optical illumination of a plurality of samples.” The patent claims an assembly for an optical read out device for biochips, in which an optical path of light emitted from samples on the chip is evaluated by a CCD camera. To create this light emission, the samples are illuminated by a light source that stimulates fluorescence in the samples. According to the patent, the light source consists of luminescent, porous silicon that allows the light source to be directly connected to the sample carrier.